FDA Clears First Neurostimulation Device for PTSD
Neurovalens' Modius Spero has become the first FDA-approved neuromodulation device for treating PTSD symptoms. Veterans are set to gain access through the VA this summer.
NOCD Launches Parent Brand Noto, Acquires PTSD Provider Rebound Health
NOCD launched a new parent brand, Noto, and acquired PTSD provider Rebound Health to expand its virtual, specialty therapy model beyond OCD into other complex mental health conditions.
presented by
Top 7 Modern AI-Powered EAP Providers for Global Workforces in 2026
Discover the top AI-powered EAP providers for 2026. Compare platforms like Kyan Health and Spring Health on triage speed, global reach, and clinical quality to transform workforce wellbeing.
Exploring How Ear-Based Stimulation May Support Stress Recovery and Post-Viral Health
Ear-based stimulation has the potential to provide health systems with a scalable, low-risk tool to address some of today’s most pressing challenges: rising rates of anxiety and depression, persistent post-viral syndromes and the long-term burden of stress-related chronic conditions.
The $232 Billion Problem: The Price of Overlooking the Impact of Trauma in the U.S.
When we talk about post-traumatic stress disorder (PTSD), a condition fundamentally born from overwhelming experiences that leave a long-term imprint on the body, our mainstream approach often feels stuck in the past.
presented by
A Path to Healing: Discovering Arizona’s PTSD Treatment Centers
Explore top PTSD treatment centers in Arizona, offering personalized care, holistic therapies and expert support to help individuals heal and reclaim their lives.
Alto Neuroscience’s Depression Trial Failure Sends Shares Into Downward Spiral
An Alto drug candidate for major depressive disorder failed to meet primary and secondary goals of a placebo-controlled Phase 2b test. The disappointing result could stymie plans for further tests of the small molecule in PTSD and bipolar depression.
presented by
Inside an Automated Healthcare Practice: Redesigning Care Around People, Not Paperwork
By reducing administrative burden and redesigning workflows around human needs, it creates space for what matters most: connection between clinicians and patients.
Shock, Fear and Anxiety – The Complexity of Breast Cancer Beyond Diagnosis
Providers should incorporate mental health screenings as a standard part of cancer care for patients and their loved ones.
Breaking Barriers: Why Accessibility Matters in PTSD Treatment Beyond MDMA
MDMA-assisted therapy (MDMA-AT) for PTSD sparked debate, primarily focused on concerns of safety and efficacy. But no matter how novel a treatment may be, if it is inaccessible to the millions of people who need it, its relevance becomes insignificant.
Why Wait? The Urgency of Accessible PTSD Treatments Now
In our eagerness for innovation, there's a risk that we ignore existing effective, readily-available treatments.
Veteran Suicide Statistics Are Horrifying — What Is the VA Doing to Help?
Research shows that an average of 17.5 veterans die by suicide each day. At ViVE 2024, Shereef Elnahal, the U.S. Department of Veterans Affairs’ under secretary for health, declared that even one veteran dying by suicide is too many — and promised that the VA is pursuing partnerships aimed at addressing this harrowing problem.
presented by
New Webinar: The Payer AI Readiness Gap: Why Better Data Will Define the Next Era of Health Plan Performance
We'll explore why the next era of payer performance will depend on building a trusted data foundation that connects people, providers, and relationships across the enterprise.
GrayMatters Health Earns FDA Clearance for PTSD Neuromodulation Device
GrayMatters Health recently received 510(k) clearance from the FDA to market its flagship product, which is a self-neuromodulation digital therapy for PTSD. The device uses neurofeedback on specific biomarkers to help patients identify and utilize their own mental strategy for lowering their emotional response.
Covid-19 PTSD in healthcare workers is real—and technology can help mitigate the impact
As the Delta variant surges on, we understand trauma for healthcare providers isn’t over, but we are hopeful that technology can make a small impact in lightening the load for our front-line heroes.
Highmark expands access to device that helps manage panic, PTSD symptoms
The payer is expanding access to telehealth coaching for Freespria's digital device, which aims to eliminate or reduce symptoms of panic disorders and post-traumatic stress disorder.
Nightware receives breakthrough designation for its PTSD nightmare therapy technology
NightWare's product learns the biometric pattern of a person's sleep and uses the wearable to intervene when a nightmare is detected, eventually adapting to a person's individual rhythms and sensitivities.
How digital therapeutics fit into the larger mental health ecosystem
An entrepreneur panel at the Manova Summit in Minneapolis, Minnesota delved into the subject of how mental health digital therapeutics augment – instead of interrupt – the work of clinicians and care professionals.